News >

Upfront Ibrutinib Continues to Impress in CLL

Surabhi Dangi-Garimella, PhD
Published: Friday, Feb 03, 2017

Paul Barr, MD

Paul Barr, MD

At 29 months’ follow-up, frontline ibrutinib (Imbruvica) reduced the risk of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the latest findings from the phase III RESONATE-2 trial presented at the 2016 ASH Annual Meeting.

“The quality of responses in patients with CLL/SLL being treated with single-agent ibrutinib continues to improve with time,” Barr concluded. “Further, rates of treatment-limiting AEs decreased over time, and a majority of the elderly patient population in the trial remains on daily ibrutinib,” said Barr.
This article was repurposed from

Barr PM, Robak T, Owen CJ, et al. Updated efficacy and safety from the phase 3 RESONATE-2 study: ibrutinib as firstline treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Presented at: 58th American Society of Hematology Annual Meeting & Exposition; December 3, 2016; San Diego, CA. Abstract 234.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication